ACTIVITY NUMBER: MHP100
ACTIVITY TITLE: Article-based Exam: Embryo Aneuploidy is Not Impacted by Selective Serotonin Reuptake Inhibitor Exposure
The Mental Health Professionals Group of the American Society for Reproductive Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. This Activity will offer 1.0 continuing education credits. The Mental Health Professional Group of the American Society for Reproductive Medicine maintains responsibility for this program and its content.
Release Date: February 1, 2018
Expiration Date: February 1, 2021
NEEDS ASSESSMENT and IDENTIFICATION OF PRACTICE GAP
It is estimated that approximately 10% of infertile women who are undergoing infertility treatment concurrently take antidepressant medication, most often selective serotonin reuptake inhibitors (SSRIs). Normal embryo development is a crucial step in successful IVF treatment and preimplantation genetic testing allows the opportunity to select normal blastocysts for transfer; embryo aneuploidy is one of the most common causes for treatment failure. Thus, it is important to determine if SSRI use is associated with aneuploidy.
This activity is based on the following: Embryo Aneuploidy is Not Impacted by Selective Serotonin Reuptake Inhibitor Exposure; Fernandez-Nieto C, Lee J, Nazem T, Gounko D, Copperman A, Sandler B. Fertil Steril 2017: 108: 973-9.
At the conclusion of the educational activity, participants should be able to:
1. State the prevalence of use of SSRIs in infertile women and their potential impact on fertility.
2. Discuss how aneuploidy may be impacted by SSRI use.
3. In consultation with the medical provider, explain to patients that this study provides reassuring evidence that SSRI use does not seem to impact the genetic makeup of their embryos.
4. Discuss the strengths and limitations of the study with regard to counseling patients.
This activity has been designed to meet the educational needs of mental health professionals involved in infertility care.
SUCCESSFUL COMPLETION REQUIREMENTS
Successful completion of this activity requires the learner to:
· View a course overview page, containing all activity and disclosure information
· Read online or print the article.
· Take an 8-question post-test, with feedback of correct/incorrect answers, scoring a minimum of 75% in three attempts.
· Complete the evaluation survey.
· Print certificate of completion.
DISCLOSURES FOR PLANNERS AND FACULTY
Andrea Braverman, PhD – Nothing to Disclose
Alice D. Domar, Ph.D. – Speaker’s bureau: Merck, Ferring; Contributor: Up to Date; Co-owner: FertiCalm, TriaDea
Janet Takefman, Ph.D. – Nothing to Disclose
Nancy A. Bowers, BSN, RN, MPH - Nothing to Disclose
Susan A. Gitlin, PhD – Nothing to Disclose
Fernandez-Nieto C – Nothing to Disclose
Lee J – Nothing to Disclose
Nazem T – Nothing to Disclose
Gounko D – Nothing to Disclose
Copperman A – Nothing to Disclose
Sandler B – Nothing to Disclose
STATEMENT OF SUPPORT
No commercial support was provided for this activity.